- LOGIN
- MemberShip
- 2026-04-09 22:54:44
- Policy
- Drug price negotiations such as Roche Evrysdi begin
- by Lee, Tak-Sun Jul 03, 2023 05:47am
- Roche's 5q spinal muscular dystrophy treatment Evrysdi Dry Syrup began negotiations with the NHIS as soon as it passed the Drug Benefit Evaluation Committee of the HIRA. Ace Pharma and H&O Pharm's multiple myeloma treatments Megval Inj. and Melpspal Inj. have also entered negotiations. The NHIS added oEvrysdi Dry Syrup 0.75 mg/mL, Melpspal Inj. 50 mg and Megval Inj. 50 mg to the negotiation list for new drug prices on the 30th. As a result, six items are currently under negotiation, including these three items, Lilly Retevmo Cap, Bayer Verquvo, and BMS Onureg. When the drug price negotiations are concluded, the benefits will be applied through a report by the Health Insurance Policy Review Committee of the Ministry of Health and Welfare. Evrysdi Dry Syrup, Megval Inj., and Melpspal Inj. were recognized for their adequacy of benefit at the Drug Benefit Evaluation Committee of the HIRA on June 1 and moved on to the negotiation stage of the industrial complex. Usually, when the MOHW orders the negotiation, the NHIS sets up a negotiation team to conduct full-fledged negotiations on the upper limit and expected usage. Evrysdi Dry Syrup is a liquid formulation that is taken PO QD and is characterized by being applicable to patients who have difficulty in treating spinal cord cavities. Motor function improvement and safety profiles were confirmed in patients of a wide range of diseases, including patients of a wide age range from 2.2 to 25 months old and patients with experience in scoliosis-related surgery. Since self-administration is possible at home, it is expected to reduce insurance financial and socioeconomic burdens by reducing the burden of indirect medical expenses such as academic, workplace interruption, transportation, and nursing. Megval and Melpspal are forms of injections with Melphalan as the main active ingredient and are national essential drugs. In Korea, Samil Pharmaceutical's Alkeran has been reported, but currently, the KODC has stopped importing and only the KODC supplies inventory as unlicensed drugs in Korea. Accordingly, Megval and Melpspal are expected to have much better accessibility to patients with multiple myeloma if they are paid.
- Company
- Pfizer, Lilly, AbbVie engage in JAKi battle in KOR
- by Nho, Byung Chul Jul 03, 2023 05:47am
- Pfizer's Xeljanz and Lilly's Olumiant are engaged in an intense competition for sales in the JAK inhibitor market. According to the distribution data of pharmaceuticals, Xeljanz (including Xeljanz XR) recorded sales of KRW 15.5 billion won last year, while Olumiant recorded KRW 15.4 billion. Although Xeljanz maintained a slight lead, Olumiant has shown a faster infiltration rate in terms of growth. Olumiant's sales in 2019, 2020, 2021, and 2022 were KRW 2.2 billion, 9 billion, 12.6 billion, and 15.4 billion, respectively, representing a 600% increase over four years. During the same period, Xeljanz recorded sales of KRW 14.6 billion, 16.2 billion, 15.1 billion, and 13.7 billion, with an additional sales increase of approximately KRW 2 billion in 2021 with the launch of Xeljanz XR. AbbVie's Rinvoq has also established its position in the market quite quickly. Its sales in 2020, 2021, and 2022 were approximately KRW 55 million, 2.6 billion, and 11.4 billion, respectively. Although the representative JAK product Xeljanz has maintained its lead so far, the drug's prospects are unpredictable from this year onwards. Already in Q1 2023, Xeljanz, Olumiant, and Rinvoq recorded sales of KRW 3.3 billion, 3.7 billion, and 3.5 billion, respectively, engaging in fierce competition. The total market size of major JAK inhibitors has risen from KRW 16.8 billion, 25.3 billion, 31.1 billion, to 42.4 billion, demonstrating a growth close to KRW 10 billion each year and is being recognized as a blue ocean market. The indications for Xeljanz Tab. (tofacitinib) include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The indications for Rinvoq PR Tab. (upadacitinib) include atopic dermatitis, in addition to the indications of Xeljanz Tab. Olumiant (baricitinib) has shown efficacy in rheumatoid arthritis, atopic dermatitis, and alopecia areata. Xeljanz XR Tab. is prescribed for the treatment of moderate-to-severe active rheumatoid arthritis in adults who do not respond adequately to or cannot tolerate methotrexate. Furthermore, Pfizer has expanded its market share by launching the JAK1 inhibitor Cibinqo in November 2021, after receiving approval from the Ministry of Food and Drug Safety. This is the fourth JAK inhibitor that has been introduced to the Korean market, and the second JAK class drug to be introduced by Pfizer, following Xeljanz. Cibinqo is expected to compete with Dupixent and Rinvoq as the treatment of severe atopic dermatitis. Olumiant is a JAK inhibitor that has gained attention as a new treatment option for alopecia areata, a condition where therapies for autoimmune disease have shown limited effectiveness. Olumiant has demonstrated significant improvements, 6-10 times more than placebo, through two large-scale clinical trials. While Rinvoq was previously reimbursed only for the treatment of moderate to severe atopic dermatitis in adults, starting from April this year, reimbursement for adolescents aged 12 and above has been approved. As a result, it is anticipated that adolescent patients with atopic dermatitis will have improved accessibility to treatment.
- Company
- Illaris for 13 pts, re-challenge to enter insurance benefit
- by Eo, Yun-Ho Jul 03, 2023 05:45am
- Illaris, a treatment for vulva diseases with only 13 patients in Korea, will try again to enter the insurance benefit zone. According to related industries, Novartis Korea submitted an application for Ilaris' benefit in April and is under discussion. However, the registration process is still expected to be difficult. The drug has already undergone two pay procedures but has not achieved its purpose. Ilaris, licensed in Korea in 2015, is a treatment for hereditary recurrence syndrome, and detailed diseases are divided according to abnormal genes. Specifically, Ilaris can be prescribed for ▲CAPS, TRAPS, HIDS/MKD, and FMF ▲ Systemic JIA in Korea. Among them, CAPS is classified again as ▲FCAS/FCU ▲MWS▲NOMID/CINCA. As there are so few target patients and the indications are complicated, it is not easy to discuss the benefits. The number of patients corresponding to various indications of Ilaris is extremely small. Some indications of Illaris do not even have a disease code or have been recently registered. In the case of CAPS, a drug called Kineret is used through the KODC. It is a drug that comes through the center rather than officially approved by the MFDS in Korea, and there are some disruptions in supply, but the communication channel is unclear and there is a limit to supply improvement. In addition, in the case of FMF, colchicine is recommended as the primary treatment, but this drug is not available in Korea. Ilaris is licensed for use in FMFs where colchicine is contraindicated or does not show an appropriate response to the highest drug dose of colchicine. However, since colchicine has not been introduced in Korea, it is difficult to use Illaris if the permission and salary problems of Kolkisin are not resolved even if the benefit is applied later. In order to solve this problem, the association is known to have applied for an increase in the salary of the drug. Since the HIRA regulations define alternative drugs as drugs included in the same treatment range in terms of permission and salary standards, it is not expected that Illaris will be able to devise a reimbursed strategy by viewing Kineret, an unlicensed emergency drug currently used only for CINCA. "There are many difficulties in many ways because the target diseases that require treatment for Illaris are detailed and the number of patients is too small," said Jeong Dae-Chul, chairman of the KCPCI (Pediatric and Adolescent Department at Seoul St. Mary's Hospital). "It is a pity for the medical staff that there are patients who are considering immigration to countries where Ilaris can be prescribed." It remains to be seen whether the drug "Ilaris" for very few patients will achieve good results this time. Ilaris is an IL-1 inhibitor recommended by international guidelines for the treatment of hereditary recurrence syndrome and is the only approved treatment in both domestic and U.S. FDA and European EMA. Ilaris is used as a benefit in a total of 30 countries based on the therapeutic effect and safety confirmed through clinical research. In Italy, Switzerland, and the United Kingdom, patients have benefited from the treatment of Illaris since 2009 in Canada and 2011 in Japan. In the UK and Canada, where Health Technology Assessment (HTA) is carried out to register new drugs like Korea, Illaris excludes cost-effectiveness evaluation and applies salaries only for PFS (CAPS, TRAPS, HIDS/MKD, FMF) indications.
- Company
- Imfinzi+Imjudo combo approved for liver cancer in KOR
- by Eo, Yun-Ho Jul 03, 2023 05:45am
- The immuno-oncology drug ‘Imfinzi’ added an indication in Korea and can be used in combination with ‘Imjudo’ in Korea. According to industry sources, AstraZeneca received approval for the combined use of Imfinzi+Imjudo from the Ministry of Food and Drug Safety on June 30th, immediately after receiving approval for its CTLA-4 inhibiting cancer immunotherapy Imjudo (tremelimumab) in Korea. The immunotherapy combo will first target liver cancer, as the combination was approved as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (liver cancer). More specifically, the approved STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) includes an initial single dose of Imjudo 300mg added to Imfinzi 1500mg, followed by Imfinzi every four weeks. The Phase III HIMALAYA trial that confirmed the efficacy of Imjudo+Imfinzi showed that patients treated with the Imjudo+Imfinzi STRIDE regimen achieved a median overall survival (mOS) of 16.4 months, reducing the risk of death by 22% compared to the current standard-of-care Nexavar. At 36 months of follow-up, the OS rate of Imfinzi+tremelimumab(Imjudo) and Nexavar was 30.7% and 20.2%, respectively, demonstrating the long-term survival benefit of the combination. The benefit of the combination therapy In the Asian subgroup analysis was also consistent with the global results. The Imjudo+Imfinzi combination is also being studied for various other types of cancer, including locoregional hepatocellular carcinoma (EMERALD-3), small cell lung cancer (ADRIATIC) and bladder cancer (VOLGA and NILE).
- Policy
- Eval period for HCV treatment shortened to 12 weeks from 24
- by Lee, Hye-Kyung Jun 30, 2023 06:01am
- The evaluation period used to determine the efficacy of chronic hepatitis C treatments has been reduced in Korea. The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) revised the 'Clinical Trial Evaluation Guidelines for Chronic Hepatitis C Treatments' on June 29 to align Korea’s clinical trial efficacy evaluation standards with the international standards and reflect the standard treatment method for chronic hepatitis C treatments. The main revisions included ▲changing the evaluation period of major efficacy evaluation indices, ▲setting toxicity test exemption standards for combination drugs, and ▲reflecting the latest chronic hepatitis C standard of care to the guidelines. Through the revision, the sustained virologic response (SVR) period that was used to evaluate the efficacy of HCV treatments will be reduced from 24 weeks to 12 weeks. The authorities had analyzed the clinical trial results of approved drugs and confirmed a correlation (98-100%) between the 12- and 24-week treatment results, and also considered its coherence with those of health agencies abroad. Also, the guidelines presented a clear standard for companies developing combination drugs to waive toxicity tests. Companies can submit their non-clinical or clinical data of the individual composite drugs and be exempt from toxicity tests if no serious toxicological concerns are present in the submitted data of each ingredient. Since the standard treatment for HCV was changed from the use of peginterferon in combination with ribavirin to direct-acting antivirals, the information on the new standard of care was also reflected in the guideline. The MFDS said, “We hope that the revised guidelines will support the development of HCV treatments, and will continue to provide information to support the development of treatments based on our expertise in regulatory science.”
- Company
- Oral AML drug Onureg can be prescribed at general hospitals
- by Eo, Yun-Ho Jun 30, 2023 06:01am
- The oral acute myeloid leukemia (AML) treatment ‘Onureg’ can now be prescribed at general hospitals in Korea. According to industry sources, BMS Korea’s new AML drug Onureg tablet (azacytidine) has passed the drug committees of Asan Medical Center and Seoul National University Bundang Hospital and is also undergoing landing processes at major general hospitals in Korea. As the company is currently negotiating drug prices with the National Health Insurance Service for reimbursement listing, preparations are in full swing to create an appropriate prescription environment. Onureg was approved in Korea in March 2022 and passed the NHIS’s Cancer Disease Deliberation Committee review in December of the same year, and then the Drug REimbrusement Evaluation Committee in April this year. The listing process took place relatively quickly since Onureg’s marketing authorization in Korea. Onureg, the only oral maintenance therapy in AML, can be prescribed to adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT) The drug demonstrated its efficacy through the Phase III QUAZAR AML-001 trial that was conducted on AML 472 patients. In the trial, Onureg prolonged survival by 10 months, showing a median overall survival (OS) of 24.7 months vs 14.8 months for patients receiving a placebo, reducing the risk of death by 31%. The percentage of patients who survived in the Onureg-treated group at 1 year and 2 years of treatment was 73% (56% in the placebo group) and 51% (37% in the placebo group), respectively, both of which higher than those in the placebo group. Also, in terms of relapse-free survival (RFS), the median RFS was 10.2 months for Onureg, 5.3 months longer than that of the placebo group, confirming its effect in reducing the risk of relapse. Meanwhile, AML is the most common but also the most fatal type of leukemia. If left untreated, 90% of the patients die within a year. Even patients that went into complete remission are at risk of relapse due to the 100 million residual leukemia cells that may remain at most. If appropriate treatment is not accompanied after complete remission, the relapse rate reaches up to 50% within 1 year, and the median overall survival (OS) after relapse is only 8 months.
- Policy
- Tx for combi of dementia/hyperlipidemia have increased
- by Lee, Tak-Sun Jun 30, 2023 06:01am
- The amount of claims for dementia treatment and hyperlipidemia has increased by more than 50% in the past two years. In the case of dementia treatment, it seems to have increased significantly as the elderly patients' visits to medical institutions decreased in 2020 due to COVID-19. The hyperlipidemia complex is interpreted as the amount of charge has also increased as the post-drugs of statin + edetimive came out all at once. In the '2022 payroll drug claim status' disclosed by the Health Insurance Review and Assessment Service on the 26th, the claim status by ATC code was compared to 2020. The drug with the largest claim in the ACT Code is the treatment for peptic ulcer and gastroesophageal reflux disease, and 1.155.8 trillion won was charged in 2022. Compared to the past 2020, this is an increase of 25.1%. However, the number of listed items decreased by 170 from 1510 to 1340. This formulation is interpreted as a significant increase in claims due to the overlap of the emergence of domestic new drug K-cap, the growth of PPI+ sodium bicarbonate formulation, and the balloon effect after the expulsion of ranitidine. Of course, the decrease in medical use due to COVID-19 in 2020 is also a major increase.. In the case of dementia treatment, such a underlying effect was more prominent. Dementia treatment claims increased by a whopping 58.4% when compared to 2020 and 2022, reflecting the decline in visits to medical institutions for the elderly in 2020. In fact, 2019 before COVID-19 had higher dementia treatment claims than in 2020. As visits to medical institutions have gradually normalized since 2021, the demand for dementia treatment has turned to an increasing trend, surpassing 400 billion won last year. During this period, the number of subsympathetic nervous system, which contains choline-alpocerate formulation, increased by 17.4%. This ingredient formulation has been judged as a selection benefit due to salary re-evaluation, but the notice is being delayed due to the suspension of execution, and the marketing of pharmaceutical companies is strengthening, so it seems that the claim is ahead of the dementia treatment. However, the number of listed items has decreased by 109 in two years. The hyperlipidemia complex also increased claims by 56% as 323 items were added in two years. Atojet generics have been pouring out since 2021, and the sales of improved new drugs from domestic companies have grown to 1 trillion won last year. The 16 top ATC code classifications for claims have all grown compared to 2020. However, direct-acting antiviral drugs, which include hepatitis B treatment and hepatitis C treatment, grew only 0.8%, making a contrast. This is interpreted because there are drugs that have a high therapeutic effect, so the number of patients does not increase. In the second year, the number of listed items has also decreased by 199.
- Opinion
- [Reporter's view] Signs of concern about the Saxenda craze
- by Jun 29, 2023 05:56am
- Five years ago, there was a Saxenda craze in Korea. People rushed to the clinics because they could easily lose weight with self-injection once a day at home, and there were no central nervous system side effects, unlike existing obesity drugs, which are psychotropic drugs. The saying, 'There is no one in Gangnam who does not take Saxenda' was circulating like a trend. Health authorities also launched an intensive crackdown on the indiscriminate use of Saxenda, but the effectiveness was temporary. Saxenda posted record sales of 42.6 billion won in the second year of domestic launch. As of 2023, the diet pill craze is showing signs of spreading once again. This is when the next-generation version of Saxenda appears. Novo Nordisk, which created Saxenda, introduced an injection that is more convenient and more effective for weight loss than Saxenda. Unlike Saxenda, which needs to be injected once daily, the new Wegovy only needs to be injected once a week. Patients participating in the trial lost an average of 15% of their body weight. Following the news that Lilly's 'Mounjaro', which is said to have the most powerful weight loss effect, was soon approved in Korea, people's expectations have risen to the peak. In the United States, Tesla CEO Elon Musk and the influencer Kardashian sisters revealed that they succeeded in dieting with these injections, causing a 'shortage phenomenon'. It is currently impossible to obtain these injections in Korea. Wegovy has been approved in Korea, but the domestic release date is undecided due to a lack of supply worldwide. There is a high possibility that it will be difficult to release within the year. As the situation is like this, some people are turning their eyes to overseas direct purchases. It is also illegally purchasing diabetes medications made with the same ingredients as oral medications, not Wegovy. In fact, this drug is for diabetes treatment, and the dose is one-third, so the purchase is pointless, but illegal purchases are not going away. Because news praising the effectiveness of a new anti-obesity treatment is pouring in every day, the targets for which this drug can be used or its side effects are often not mentioned or forgotten. The focus is on just how much weight you lose. First, in the United States, where the craze took place, purchasing and taking Wegovy raw materials at random has emerged as a social problem. Korea, where Wegovy will be released in the future, will not be an exception. In order to receive a prescription for injections, it may be common to run 'open runs' in hospitals or engage in illegal transactions by paying a higher price. There is a high risk that exaggerated advertisements using people's desire to buy will also pour out. These are examples that have already appeared in the Saxenda craze. Preemptive efforts are needed to prevent indiscriminate abuse of obesity drugs. When this drug can be used and when it should not be used, side effect information should be clearly communicated and safe usage instructions should be provided. It is also necessary to pay close attention to the overuse of exaggerated advertisements by some hospitals. There is something we should also remember. A new drug that claims to have lost more than 10 kg, it is difficult to expect such an effect if the participating patients are all overweight and obese and their body mass index (BMI) is less than 30 kg/m2. At the time of the clinical trial, the patients controlled their diet and exercised together. In the end, medicine is the only medicine, and in the end, if you do not continue to control your diet and exercise appropriately, weight loss is only temporary.
- Company
- Unlisted Trajenta patents hinder early release of generics
- by Kim, Jin-Gu Jun 29, 2023 05:56am
- The patent challenges made for the early release of antidiabetic ‘Trajenta (linagliptin)’ is going through a rough patch. The patents that the original company registered with KIPO but not with the MFDS are acting as obstacles. For the generics companies that filed patent challenges, a prolonged dispute is now inevitable as they would have to overcome all of Trajenta's unlisted patents, which may be up to 10 or more, in order to release their generics. Number of claims have been filed against Trajenta’s unlisted patents... 8 in total in 9 months Pic of TrajentaAccording to industry sources on the 28th, Genuone Sciences filed a trial against Boehringer Ingelheim to invalidate Trajenta’s use patent (10-2427380). The use patent was not listed on the Ministry of Food and Drug Safety’s Green List. Genuone Sciences had previously filed claims to has also requested a trial on 5 other unlisted patents of Trajenta. In September last year, the company filed a claim to confirm the passive scope of rights on Trajenta’s substance patent 10-2051281, and invalidation trials on 3 use patents (1558938/10-1655754/10-1806786) and 1 manufacturing method patent (10-1541791) in October last year. In addition, two other challenges are being made to Trajenta’s unlisted patents. In addition to Genuone Sciences, Sinil Pharmaceutical, Korea United Pharm, Hutecs Korea Pharmaceutical, Korea Biochem, and Hallim Pharmaceutical are also challenging Trajenta’s patent. In April this year, the companies requested a passive trial to confirm the scope of rights on two Trajenta formulation patents (10-1710881/10-1855323). This means that 8 of Trajenta’s unlisted patents have been targeted by generic companies in about 9 months from last September. Generic companies have no problem obtaining authorization as latecomer drugs even without overcoming unlisted patents. However, the situation is different when the companies actually release their generic products. Without overcoming all of the patents, the companies become embroiled in patent infringement lawsuits with the original company. If the original drug’s company files a petition for a preliminary injunction to block the release of the product when it files the patent infringement lawsuit, the release date of the generic company’s product may be delayed. In addition, if the company loses the patent infringement lawsuit, it may lead to additional lawsuits for damages. Trajenta’s last listed patent expires in June next year... Unlisted patents remain barriers The generic companies have succeeded in avoiding or invalidating most of Trajenta’s unexpired and listed patents on MFDS’s Green List. Boehringer Ingelheim, the original company, listed 6 patents for Trajenta in the Green List. Among them, one substance patent 1 (10-1150449) expired in September last year. Use patents 1 (10-1111101) and 2 (10-0926247) also expired in August and September last year, respectively. In 2016, the generic companies succeeded in evading or invalidating Trajenta’s substance patent (10-1478983) and crystalline patent (10-1452915) which were set to expire in April 2027. Therefore, the only listed patent that has a term remaining is Trajenta’s substance patent 2 (10-0883277), which is set to expire in June next year. Therefore, on the surface, the early release of generics seems possible after June next year. In fact, generic companies have originally planned to release their generic versions early, in line with the expiration of the second substance patent in June next year. However, the patents that were not listed on the Green List are acting as obstacles to the early release of their generics. Since releasing generic drugs without overcoming the unlisted patents will lead to patent infringement, the generic companies must overcome all of the patents before launching their generic drugs. "There may be up to or over 10 unlisted Trajenta patents”... increases the burden of dispute on generic companies↑ The problem is that Trajenta has too many unlisted patents. The industry expects that there may be a total of more than 10 unlisted patents, including those for which claims are yet to be filed. This means that there are more than 10 trials that generic companies would need to win additionally for the early release of their Trajenta generics. From the perspective of generic companies, the burden of concurrently ongoing patent disputes is not small. In particular, since they are not listed on the Green List, generic companies have to search for the patent information and individually request trials, which is also a hassle. Given this situation, the industry predicts there is a high possibility that the patent dispute related to Trajenta will continue in the long-term. An industry official said, “Because they are not listed on the Green List, generic companies have to find hidden patents one by one and request a trial. Moreover, when the original drug’s company applies to register a patent to the KIPO, the company does not enter the product or brand name in its inventions, therefore, finding the patents is in itself very cumbersome, and there is always the possibility that they may miss some patents.”
- Company
- SK Plasma supplies 39 billion worth of blood products
- by Jun 29, 2023 05:56am
- SK Plasma announced on the 28th that it will begin full-fledged production this month after receiving product approval for blood products (albumin and immunoglobulin) from the Singapore Health Authority (HSA). The company will independently supply a total of 30 million dollars (39 billion won) worth of blood derivatives over the next six years, starting with the initial export in the fourth quarter. When the Singapore health authorities send plasma secured through their own blood source to SK Plasma, SK Plasma produces finished blood products such as albumin using the plasma as raw material at the Andong plant and sends it to Singapore. In 2022, Singapore's health authorities designated SK Plasma's blood product as a priority review target. As a result, the approval review process, which normally takes 18 months, was shortened by 5 months. Blood products are medicines that use blood as raw material, and are manufactured in the form of medicines such as albumin and immunoglobulin by fractionating and refining blood components. It is used as an essential treatment in various fields such as shock caused by excessive bleeding, congenital immunodeficiency disease, and hemophilia. In a national disaster situation, blood products such as albumin and immunoglobulin are widely needed, so they are designated and managed as essential national medicines. The Singapore government is supplying blood products to its citizens in the form of a national tender. In the 2021 blood product bidding by the health authorities, SK Plasma was selected as the first Asian country to consign production of the entire volume. SK Plasma plans to process and export approximately 20,000 liters of blood products annually to Singapore. The Singapore plasma, which has been stocked since this year, will be put into production soon. In addition, it plans to accelerate its global business by cooperating with foreign countries to introduce local raw material plasma and promote consignment production. Kim Seung-Joo, CEO of SK Plasma, said, "This toll processing of blood products is an example of SK Plasma's technological prowess being recognized as the first exclusive toll processing export of a country at the EU GMP level." We plan to continue to expand," he said. SK Plasma is promoting the construction of a blood derivatives plant in Indonesia. In March, a blood product plant near Jakarta, Indonesia, which can process 1 million liters of plasma raw material per year, is under construction with the goal of completion in 2025.
